Envisagenics

Envisagenics is a biotechnology company that has developed a unique platform called SpliceCore to identify, test, and validate drug targets.

Headquarters

Year Founded

Search Tags

AI biotechnology, RNA therapeutics, machine learning

About Us

Envisagenics is an AI-driven biotechnology company that specializes in RNA splicing research and therapeutic development. They use their proprietary platform, which combines artificial intelligence and machine learning, to analyze RNA sequencing data and identify novel RNA splicing variants associated with diseases.

Trending Companies

Latest Articles

Engineer intelligent, AI-driven supply chain operations. Discover what next-generation leaders must master to design resilient, data-driven, high-performing global networks.

The Future of Supply Chain Leadership: Why the Next Generation Will Engineer Intelligence, Not Just Manage It

Supply chain leadership is being redefined by AI, intelligent automation, and agentic decision-making, demanding leaders who can engineer end-to-end intelligence rather than simply manage workflows. This article explores how next-generation supply chain leaders will combine data, algorithms, and human judgment to build resilient, adaptive, and high-performing global operations.

Read More >
Medicare will pilot AI-driven prior authorization in 2026 across six states, targeting high-risk services while clinicians make final decisions.

AI-Powered Prior Authorization Comes to Traditional Medicare

Traditional Medicare will pilot AI-assisted prior authorization in 2026 across six states, focusing on high-risk outpatient services. Clinicians retain final say, but incentives and access concerns loom as CMS tests fraud reduction and “gold card” exemptions. Here’s what providers and patients should know.

Read More >